Ångström AI logo
YC S24

Ångström AI

Gen AI molecular simulations that reproduce wetlab results

About

Angstrom AI builds GenAI-based molecular simulations to substitute wet lab experiments in the pre-clinical drug development pipeline. We are a team of 2 PhD's and 2 Professors from the University of Cambridge who decided to start a company together after we realised how to combine breakthoughs in our research in quantum-accurate models of physics and generative AI models. Our Biotech/Pharma clients can verify the efficacy and safety of new drug candidates using our computer simulations, which match the accuracy of wet lab experiments, but are over 100x faster. We achieve this accuracy by constraining our genAI-based simulations to obey the laws of physics, avoiding the hallucinations seen in other GenAI technologies. Since joining YC, Angstrom AI has developed the first physically accurate gen-AI based simulation of multiple molecules interacting. We have published the first molecule water solubility results with accuracy within the error range of wet lab experiments. We have also kicked-off a 150K pilot project with a pharma company to apply our tech to estimating solubility in their drug development pipeline.

Founders

Family Office Investors

Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Ångström AI.

See family office activity

Industry & Focus

HealthcareDrug Discovery and DeliveryAI-powered Drug DiscoveryArtificial IntelligenceBiotechDrug discoveryAI